Clinical Trials in Austin

Showing 4621-4640 of 15,205 trials

A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies

NCT05032040

This is a Phase 2, multicenter, two-stage, open-label, parallel-group study designed to evaluate the efficacy and safety of vudalimab (XmAb20717) in patients with selected advanced gynecologic and genitourinary malignancies.

Ovarian CancerClear Cell CarcinomaEndometrial Cancer+2 more

Xencor, Inc.170 participantsStarted Jul 2022

Prescott, Arizona, United States • La Jolla, California, United States • Los Angeles, California, United States +14 more locations

TERMINATEDPhase 2< 1 mile

Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Medium Dose Inhaled Corticosteroid (ICS).

NCT01396278

The aim of the study is to assess and compare efficacy and safety of BI 54903 at three different dosages (b.i.d)., fluticasone propionate hydrofluoroalkane (HFA) metered dose inhaler (MDI) at a dose of 440 mcg b.i.d and low dose fluticasone propionate 88 mcg b.i.d. over an 8-week treatment period in asthmatic patients aged 12 to 65 years inadequately controlled medium dose ICS therapy as demonstrated by a decrease in forced expiratory volume in one second (FEV1) range 10 to 25 % and an asthma control questionnaire-6 (ACQ-6) equal or greater than 1.5 at time of randomisation.

Asthma

Boehringer Ingelheim9 participantsStarted Jul 2011

Fountain Valley, California, United States • Fullerton, California, United States • Long Beach, California, United States +34 more locations

A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies

Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Medium Dose Inhaled Corticosteroid (ICS).

Find Trials by Condition in Austin

A Study to Investigate the Effect of Food on Camlipixant Concentrations in Healthy Participants

A Phase 2b Study of BNC210 Tablet Formulation in Adults With Post-Traumatic Stress Disorder (PTSD)

A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSD

Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis

This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects with Any Progressive Locally Advanced or Metastatic Solid Tumors

LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib

A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006)

myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home

Framing Eighteen Coils in Cerebral Aneurysms Trial

Different Doses of Naronapride Vs. Placebo in Gastroparesis

Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

A Study of SGN-ALPV in Advanced Solid Tumors

Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy

Safety and Immunogenicity of CodaVax-RSV in Seropositive and Seronegative Children

Repigmentation of Stable Vitiligo Lesions Using Spray-On Skin™ Cells

A Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of PGDM1400LS Alone and in Combination With VRC07-523LS and PGT121.414.LS in Healthy, HIV-uninfected Adult Participants

Open-Label Study of Setmelanotide in Hypothalamic Obesity

A Food Additive Removal Diet for Pediatric Eosinophilic Esophagitis